tri-virus specific cytotoxic t-cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01460901)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human adenovirusImmunity, active
Human adenovirus immunity, active
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tri-virus specific cytotoxic t-cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01460901 | Phase 1 | Oct 1, 2011 | National Heart, Lung, and Blood Institute (NHLBI), University of Kansas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2011 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2011 |
2 organizations
Page 1 / 1